Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,213 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombotic Disorder Clear all
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 4 Interventional Results available

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Apixaban 2.5 MG, Placebo oral tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
eltrombopag
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Nyack, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

NCT00071032
View directory record Official record
Conditions
Anemia, Hematologic Diseases, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Thromboembolism, Pneumonia, Cerebrovascular Accident
Interventions
Liberal (10 g/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years and older
Enrollment
2,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Jun 25, 2026, 11:05 PM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

NCT04191928
View directory record Official record
Conditions
Pancreas Cancer, DVT, Pulmonary Embolism
Interventions
Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

Examining the Experiences of Children With Blood Disorders

NCT04600609
View directory record Official record
Conditions
Blood Disease, Thrombotic Disorder, Venous Thromboembolism, Hemostatic Disorder, Bleeding Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

NCT04879407
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
98,947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 25, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544
View directory record Official record
Conditions
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions
ARC 1779 Placebo, ARC1779 Injection
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 4 Interventional Results available

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass

NCT05426031
View directory record Official record
Conditions
Coagulation; Intravascular
Interventions
Protamine fixed dose, Protamine ratio dose
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jun 25, 2026, 11:05 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Jun 25, 2026, 11:05 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluating the Use of Grip Exercises to Decrease Deep Vein Thrombosis in Adult Patients With PICC Lines

NCT06370702
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Handgrip Exercises
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Lucentis for Central Retinal Vein Occlusion (CRVO)

NCT00406796
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Jun 25, 2026, 11:05 PM EDT
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational Results available

The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial

NCT03040622
View directory record Official record
Conditions
Left Atrial Appendage Closure, WATCHMAN Device Implantation
Interventions
WATCHMAN Left Atrial Appendage Closure
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

ATHN 2: Factor Switching Study

NCT02546622
View directory record Official record
Conditions
Hemophilia
Interventions
Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Biological
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
27
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain

NCT00855231
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Pulmonary Embolism, Aortic Dissection
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 26, 2017 · Synced Jun 25, 2026, 11:05 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

The Protrieve PROTECTOR Study

NCT06495996
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
Percutaneous mechanical thrombectomy (PMT)
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Newport Beach, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

NCT00055159
View directory record Official record
Conditions
Thrombosis
Interventions
Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT06118957
View directory record Official record
Conditions
Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jun 25, 2026, 11:05 PM EDT